Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Médica Electrónica
versión On-line ISSN 1684-1824
Resumen
SANCHEZ-PEREZ, Diriana Bárbara et al. Efficacy and safety of Proctokinasa® suppository in the treatment of acute pelvic inflammatory disease. Rev.Med.Electrón. [online]. 2024, vol.46 Epub 30-Ene-2024. ISSN 1684-1824.
Introduction:
Acute pelvic inflammatory disease is a common entity in young women of reproductive age and it is a leading cause of infertility. The search for an effective and safe anti-inflammatory treatment that relieves pain, avoids complications and sequels, it is priority for its treatment.
Objective:
To evaluate the efficacy and safety of the treatment with Proctokinasa® in acute pelvic inflammatory disease grades I and II.
Materials and methods:
An open, controlled clinical trial was carried out from January 2017 to January 2018 which included 76 patients diagnosed with acute pelvic inflammatory disease in primary health care; they were randomize assigned to two treatment groups: Proctokinasa® main group, who received one unity/8h for 2 days, and the Piroxican group, 1 suppository of 20 mg/24h per 7 days. The recommended oral antibiotic therapy was started simultaneously. Clinical and ultrasound response to treatment were evaluated. Adverse events were evaluated.
Results:
Clinical response was stated after 72 hours of treatment inmore than 50% of the patients in both groups, and it was 100% for the Proctokinasa® group in the last two evaluations (days 10 and 15). Remission of ultrasound alterations was evident in 96.9% of the Proctokinasa® group. Adverse events were few and mild.
Conclusions:
The use of Proctokinasa® was effective and safe in the treatment of acute pelvic inflammatory disease grades I and II.
Palabras clave : acute pelvic inflammatory disease; Proctokinasa®, controlled clinical trial..